First-Trimester Biomarker May Help Identify Early GDM Risk

This article originally appeared here.
First-Trimester Biomarker May Help Identify Early GDM Risk
First-Trimester Biomarker May Help Identify Early GDM Risk

(HealthDay News) – Glycosylated fibronectin may be able to identify pregnant women during the first trimester at risk for developing gestational diabetes mellitus (GDM), according to a study published online Aug. 5 in Obstetrics & Gynecology.

Juha P. Rasanen, MD, PhD, from the Oregon Health and Science University in Portland, and colleagues measured serum concentrations of glycosylated (Sambucus nigra lectin-reactive) fibronectin, adiponectin, sex hormone-binding globulin, placental lactogen, and high-sensitivity C-reactive protein (CRP) in 90 pregnant women (who subsequently developed GDM) at 5–13 weeks of gestation and in 92 control participants.

The researchers observed a significant association between GDM and first-trimester serum concentrations of glycosylated fibronectin, adiponectin, high-sensitivity CRP, and placental lactogen. Glycosylated fibronectin remained independently associated with GDM after adjusting for maternal factors and other markers. Above a threshold of 120mg/L, glycosylated fibronectin levels correctly identified 57 GDM case group participants, with a positive predictive value of 63% and a negative predictive value of 95%, at a population prevalence of 12%.

"First-trimester glycosylated fibronectin is a potential pregnancy-specific biomarker for early identification of women at risk for GDM," the authors write.

Several authors disclosed financial ties to DiabetOmics, which funded the study.

Abstract
Full Text (subscription or payment may be required)